SAVA | Cassava Sciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	26.50 - 29.79
52 Week Range	8.79 - 42.20
Beta	-0.25
Implied Volatility	129.14%
IV Rank	31.50%
Day's Volume	1,536,114
Average Volume	3,337,841
Shares Outstanding	47,976,200
Market Cap	1,291,039,542
Sector	Healthcare
Industry	Biotechnology
IPO Date	2000-07-14

Valuation
Profitability
Growth
Health
P/E Ratio	-9.51
Forward P/E Ratio	-10.99
EPS	-2.83
1YR Price Target	84.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	29
Country	USA
Website	SAVA

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.

SAVA's peers: ALT, ANVS, ATNM, AVXL, BCRX, INMB, AXSM, RVPH, MCRB, BIVI, CGTX, CVAC, RETA, KRYS, VIR, PPCB, EXEL, TGTX, VKTX, MDGL, BTAI, SLS

*Chart delayed

Analyzing fundamentals for SAVA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see SAVA Fundamentals page.

Watching at SAVA technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on SAVA Technicals page.